Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 26, Number 8—August 2020
Investigation and Serologic Follow-Up of Contacts of an Early Confirmed Case-Patient with COVID-19, Washington, United States
We describe the contact investigation for an early confirmed case of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in the United States. Contacts of the case-patient were identified, actively monitored for symptoms, interviewed for a detailed exposure history, and tested for SARS-CoV-2 infection by real-time reverse transcription PCR (rRT-PCR) and ELISA. Fifty contacts were identified and 38 (76%) were interviewed, of whom 11 (29%) reported unprotected face-to-face interaction with the case-patient. Thirty-seven (74%) had respiratory specimens tested by rRT-PCR, and all tested negative. Twenty-three (46%) had ELISA performed on serum samples collected ≈6 weeks after exposure, and none had detectable antibodies to SARS-CoV-2. Among contacts who were tested, no secondary transmission was identified in this investigation, despite unprotected close interactions with the infectious case-patient.
In December 2019, a viral pneumonia outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, before spreading rapidly to other provinces in China and then internationally (1). On January 20, 2020, the Centers for Disease Control and Prevention (CDC) confirmed a US case of coronavirus disease (COVID-19), the disease caused by SARS-CoV-2, in a traveler who had recently returned to Washington state from Wuhan (2). We investigated contacts of the confirmed case-patient to describe transmission to inform public health recommendations and control measures.
Washington state and local health officials interviewed the case-patient to identify contacts and activities during time of symptom onset until appropriate isolation of the patient. Because contact investigations for COVID-19 had not been conducted in the United States, the Washington State Department of Health (WA DOH), in consultation with CDC, developed contact definitions based on the best evidence available at the time, which are not necessarily consistent with those currently in use (Table 1). We tailored the contact definitions after the case-patient interview based on the known movement and activities of the case-patient. We categorized contacts into community or healthcare contacts. For this investigation, we defined community contact as any close contact (being within 6 feet of the case-patient) for a prolonged time (>10 minutes); being an office co-worker of the case-patient with close contact of any duration; contact with infectious secretions from the case-patient; or sharing a healthcare waiting room or area during the same time and up to 2 hours after the case-patient was present. Transient community interactions (e.g., grocery store cashiers) were not considered community contacts. Healthcare contact included any face-to-face interaction between healthcare personnel (HCP) and the case-patient without wearing the full personal protective equipment (PPE) that was recommended at the time of the investigation (i.e., gown, gloves, eye protection, and N95 respirator) or potential contact with the case-patient’s secretions by HCP without wearing full PPE. HCP who cared for the patient after patient isolation while wearing the full recommended PPE were monitored but not included in this contact investigation report.
The local health departments actively monitored identified contacts during the 14 days after the last exposure date to the case-patient (i.e., the monitoring period). Active monitoring consisted of daily telephone calls or text messages to ask the contacts whether they had measured fever (>100.4°F or >38°C) or symptoms including cough, shortness of breath, chills, runny nose, body aches, sore throat, headache, diarrhea, nausea, or vomiting. The local health department supplied thermometers to contacts without a home thermometer. Contacts who developed signs or symptoms during the monitoring period were assessed as persons under investigation (PUIs) for SARS-CoV-2 infection, and nasopharyngeal (NP) and oropharyngeal (OP) swabs were obtained for testing.
Concurrently with mandatory active monitoring, CDC, WA DOH, and the local health departments conducted an enhanced contact investigation. This investigation was implemented after the urgent public health activities of identifying contacts and initiating active monitoring procedures were begun and was voluntary. The enhanced contact investigation included an in-depth interview using a standardized questionnaire and collection of NP and OP specimens and serum samples. We approached all identified community and healthcare contacts by telephone for participation. For contacts who agreed, we conducted the interview by telephone or during in-person household visits, depending on the contact availability at the time of the initial outreach. The questionnaire included demographic characteristics, medical history, and type and duration of the exposure to the case-patient. Exposure types assessed on the questionnaire were “physically within 6 feet of the case-patient,” “had face-to-face interaction,” “had direct physical contact,” and “traveled in the same vehicle, sitting within 6 feet of the case-patient.” For HCP, we also obtained data regarding healthcare-specific exposures and PPE use during the encounter. For all asymptomatic contacts who agreed, we collected NP and OP specimens and serum samples during the monitoring period to test for SARS-CoV-2 by molecular and serologic methods. We tested symptomatic contacts under PUI protocols. We approached participants in the initial enhanced investigation ≈6 weeks after last exposure to the case-patient for collection of follow-up serum samples.
NP and OP swabs were shipped to CDC and tested for SARS-CoV-2 using a real-time reverse transcription PCR (rRT-PCR) assay with 3 targets (N1, N2, and N3), as previously described (3). The human RNase P gene was used as an internal human gene to confirm RNA quality. Serum samples were tested at CDC using a SARS-CoV-2 ELISA with a recombinant SARS-CoV-2 spike protein (courtesy of Dr. Barney Graham, National Institutes of Health, Bethesda, MD, USA) as an antigen (4). Protein ELISA 96-well plates were coated with 0.15 μg/mL of recombinant SARS-CoV-2 spike protein and ELISA was carried out as previously described (5). An optimal cutoff optical density value of 0.4 was determined for >99% specificity and 96% sensitivity (B. Freeman et al., unpub. data; https://www.biorxiv.org/content/10.1101/2020.04.24.057323v1). Specimens with total anti-SARS-CoV-2 antibody titers >400 were considered seropositive. Serum samples from the case-patient were used as a positive control and commercially available serum collected before January 2020 from an uninfected person as a negative control.
This public health investigation was determined to be non-research by CDC and WA DOH. Thus, it was not subject to review by either institutional review board.
The case-patient, a 35-year-old man, was asymptomatic when he returned home to Washington from Wuhan on January 15, 2020 (2). During the next 2 days, he developed a cough (day 1 of illness) and chills (day 2) while continuing to work in an office setting. He reported feeling feverish on day 3, a weekend day. On day 4, he went to an urgent care clinic, where he was identified as meeting the PUI criteria at the time for COVID-19; NP and OP swabs and serum samples were collected and sent to CDC for SARS-CoV-2 testing (6). Upon laboratory confirmation as a COVID-19 case-patient (day 5), he was hospitalized for isolation and clinical observation (Figure 1).
The investigation identified 50 contacts of the case-patient while he was symptomatic, including 42 community contacts (11 office co-workers and 31 waiting room contacts at the urgent care clinic) and 8 healthcare contacts (Table 1). The case-patient lived alone, so he had no household contacts. Among the 50 contacts, the median age was 44 years (range <1–86 years); 25 (50%) were male. All 50 contacts were actively monitored daily. Eight (16%) developed symptoms, including cough (n = 6), headache (n = 5), runny nose (n = 5), sore throat (n = 4), or fever (n = 1), during their monitoring period and were assessed as PUIs; none required hospitalization (Table 2).
Of the 50 contacts, 38 (76%) participated in the voluntary enhanced contact investigation and completed the standardized questionnaire interview (Figure 2). Among these, 24 (63%) had >1 underlying condition, including asthma (n = 10; 26%), hypertension (n = 7; 18%), type 2 diabetes mellitus (n = 4; 11%), or pregnancy/postpartum (n = 2; 5%) (Table 3).
Eleven office co-workers were identified as having had close contact (<6 feet) with the case-patient. Four (36%) co-workers were exposed over the course of 1 day and 7 (64%) were exposed over the course of 2 days. The duration of close contact ranged from 2 to 90 minutes (<10 minutes, n = 2; 10–15 minutes, n = 3; 60–90 minutes, n = 6). All 11 co-workers reported face-to-face interaction with the case-patient, and 6 (55%) had direct physical contact (e.g., shaking hands, touching shoulder). Although the case-patient admitted symptoms of cough while at the office, no co-workers recalled being within 6 feet of the case-patient while he was coughing. On day 2 of illness, the case-patient attended a 2-hour lunch with 7 co-workers. Three co-workers traveled in the same vehicle as the symptomatic case-patient for a total of 30 minutes on the way to and from lunch.
All 8 HCP had interactions with the case-patient without wearing the full recommended PPE. One HCP was a public health employee who briefly visited the case-patient’s home and had a face-to-face conversation without wearing PPE; however, further details of this HCP’s exposure were not available because the contact did not participate in the enhanced contact investigation. The remaining 7 HCP worked at the urgent care clinic where the patient initially sought care: a receptionist, medical assistant, nurse, physician assistant, radiograph technician, and 2 environmental services (EVS) workers.
All 7 HCP at the urgent care clinic participated in the enhanced contact investigation. Of those, 5 (71%) had face-to-face interaction with the case-patient; the case-patient was wearing a facemask for most encounters. Duration of exposure among HCP ranged from 5 to 25 minutes (<10 minutes, n = 1; 10–15 minutes, n = 3; 15–30 minutes, n = 1). Three HCP had direct physical contact with the case-patient while the HCP was wearing a facemask and no gloves; HCP 1 positioned the case-patient for chest radiograph imaging, HCP 2 took the patient’s vital signs, and HCP 3 examined the case-patient and performed an OP exam. When obtaining the NP and OP swabs, HCP 3 wore an N95 respirator, face shield, and gloves but no gown. HCP 4 had direct physical contact while wearing an N95 respirator and gloves when drawing blood and processing specimens. Neither HCP wearing N95 respirators had been fit tested within the last year. The EVS workers cleaned the clinic >8 hours after the case-patient left the urgent care clinic. While cleaning, 1 EVS worker wore gloves consistently but the other did not.
The 31 waiting room contacts included patients and persons accompanying them who were likely to be in the waiting room at the same time as the case-patient or up to 2 hours after the case-patient was taken to a room. According to the sign-in sheet, ≈7 contacts overlapped in the waiting room with the case-patient. Because the case-patient was anonymous to the waiting room contacts, the 20 (65%) interviewed waiting room contacts were unable to describe their exposure type and duration. However, they consistently described being given a facemask if they had respiratory symptoms, staying >6 feet apart from other waiting room patients, and sitting <30 minutes in the waiting room. The case-patient said that he did not interact directly with any of the waiting room contacts.
Of the 50 contacts, 37 (74%) had NP and OP specimens collected and tested for SARS-CoV-2; 33 (66%) had specimens collected once, and 4 (8%) had specimens collected twice (Table 3). Of the 8 (16%) contacts who were assessed as PUIs during the investigation, all were tested for SARS-CoV-2 infection while symptomatic. Among asymptomatic contacts, the NP and OP specimens were collected a median of 11 days (range 9–13 days) from the last date of exposure. All NP and OP specimens tested negative for SARS-CoV-2 by rRT-PCR, including those from PUIs. Serum samples were obtained from 32 (64%) of the 50 contacts (Table 3). Initial serum was obtained from 28 (56%) contacts, and follow-up serum was obtained from 23 (46%) contacts; none had detectable antibodies to SARS-CoV-2.
This investigation identified no secondary cases among close contacts of this early US COVID-19 case-patient by molecular or serologic methods. Systematic contact tracing initiated soon after case confirmation identified office co-workers, HCP, and persons who overlapped in an urgent care clinic waiting area as contacts of the symptomatic case-patient with potential risk for infection. All 50 contacts were actively monitored daily for development of signs or symptoms consistent with COVID-19 and were assessed as PUIs if signs or symptoms developed. During the 14 days after last exposure of the identified contacts, testing of respiratory specimens by rRT-PCR of all symptomatic contacts (PUIs) and most asymptomatic contacts revealed no evidence of secondary transmission. Serum specimens collected ≈6 weeks after the last exposure for 23 (46%) contacts showed no evidence of SARS-CoV-2 antibodies, providing additional confirmation that secondary transmission did not occur among tested contacts.
The lack of transmission among contacts in this investigation is similar to findings reported in other early systematic contact investigations of case-patients with COVID-19 in January and February, in which only close household contacts were infected (8–11). One potential explanation for the lack of transmission among tested contacts may be the nature of the community exposures to the case-patient compared with the more intimate and continuous exposures that would typically be experienced by household contacts. Given the current situation of sustained community transmission of SARS-CoV-2, it is of interest that there was no evidence of transmission to co-workers, despite a 60–90 minute lunch together and travel together in a car while the case-patient was symptomatic, albeit with mild symptoms (12).
Similar to other reported COVID-19 case-patients, this case-patient had SARS-CoV-2 detected from NP and OP specimens at very low cycle threshold values (NP 18–19, OP 21–22) at the time of first testing at the urgent care clinic (day 4 of illness), indicating a high viral load (2,13). Of note, the case-patient wore a facemask in the urgent care clinic waiting room and during most of the healthcare encounters, except during examination and respiratory specimen collection. In addition, HCP who interacted with the case-patient all wore partial PPE, which included a facemask or an unfitted N95 respirator. Influenza studies found that patients or HCP wearing a facemask is associated with a reduced risk of nosocomial transmission (14). A COVID-19 contact investigation described 35 HCP who wore facemasks during a prolonged exposure to an aerosol-generating procedure for a patient with COVID-19; none acquired infection (15). These investigations suggest that facemasks worn by the case-patient or the HCP might have helped prevent secondary transmission of COVID-19 in the healthcare setting, although additional studies are needed.
A unique aspect of our contact investigation was the inclusion of serologic testing, which strengthened the conclusion that secondary transmission did not occur among tested contacts. Molecular testing detects viral RNA present in an active infection and is dependent on sampling location, technique, and the timing. Although the serologic assay used does not necessarily confirm current infection, it enables detection of seroconversion, indicating a history of SARS-CoV-2 infection. SARS-CoV-2 antibodies are detectable in most persons with COVID-19 within 1–3 weeks after illness onset, although more data are needed to determine whether all persons infected with SARS-CoV-2 develop detectable antibodies (16,17). Use of serologic testing complements molecular diagnostics and adds to the ability to detect asymptomatic infections or infections that occurred in persons who did not have testing performed during the acute phase of illness.
This contact investigation had limitations. The investigation involved a single case; thus, only transmissions related to specific interactions for a single case are assessed. The case-patient had no household contacts, and all HCP contacts reported using at least partial PPE. Therefore, these findings cannot be generalized for persons with other types of contacts. Furthermore, not all contacts were tested. Testing was biased toward contacts who knew the case-patient personally (office co-workers) or provided direct care for the case-patient (HCP). Most contacts were tested by rRT-PCR assay at one point during their monitoring period; we cannot exclude that timing of NP and OP swab collection could have affected the ability to capture asymptomatic infection. In addition, details of the exposure history, particularly exposure duration and frequency, are subject to recall bias. Contacts of the case-patient before symptom onset were not included in this investigation, including airplane contacts from the day before the case-patient’s symptom onset. Finally, contact identification could have been incomplete. We cannot rule out the possibility that certain interactions not captured in the contact investigation, including those classified as transient interactions, could have resulted in transmission, although unprotected prolonged exposures described in this report did not result in transmission.
This contact investigation provides detailed exposure information regarding prolonged close interactions among tested contacts that did not result in secondary transmission of SARS-CoV-2. Multiple factors likely influence transmissibility of a given COVID-19 case-patient, including viral load, symptom severity, aerosol generation, host factors in the case-patient and contact, use of protective equipment (e.g., facemask use by the case-patient), and exposure type, timing, duration, setting, and frequency. Further investigations are needed to determine host factors and exposures associated with increased transmission.
Contact investigations coupled with laboratory testing remain crucial public health tools for identifying, isolating, and preventing additional COVID-19 cases. Serologic methods, in addition to molecular detection, are a valuable tool in improving our understanding of the rate of asymptomatic infection. Understanding more about the occurrence of asymptomatic and presymptomatic infection and its contribution to SARS-CoV-2 transmission is critical for guiding community mitigation strategies and infection prevention and control recommendations.
Dr. Chu is an Epidemic Intelligence Service officer and Dr. Freeman-Ponder is a Laboratory Leadership Service fellow in the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Dr. Chu’s research interests include viral respiratory and vaccine-preventable diseases, and Dr. Freeman-Ponder’s research interests include immunological and molecular epidemiologic studies of infectious diseases.
We thank the following persons at the Washington State Department of Health: Elyse Bevers, Mike Boysun, Tia Dostal, Jessica Gant, Romesh Gautom, Nicholas Graff, Cynthia Harry, Brian Hiatt, Esther Lam, Larissa Lewis, Kathy Lofy, Jasmine Matheson, Patricia Montgomery, Denny Russell, John Wiesman; and at the Centers for Disease Control and Prevention: Sharad Aggarwal, Catherine Bozio, How-Yi Chang, Hsin Chien, Mila Cohen, Rebecca Dahl, Mathew Esona, Leora Feldstein, Paul Gastanaduy, Rashi Gautam, Ruth Link-Gelles, Connor Hoff, Jennifer Hunter, Laurel Jenkins, Nazia Kamal, Shifaq Kamili, Michelle Kautz, Lindsay Kim, Steven Langerman, Jessica Leung, Brian Lynch, Lakshmi Malapati, Claire Mattison, Allison Miller, Ruth Moro, Janna’ Murray, Manisha Patel, Makisha Rogan, Senthil Kumar Sakthivel, Sarah E. Smith-Jeffcoat, Jennifer Thomas, Lijuan Wang, John Watson, Brett Whitaker, and Shannon York.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
- Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al.; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–36.
- Centers for Disease Control and Prevention. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel; 2020 [cited 2020 Mar 30]. https://www.fda.gov/media/134922/download
- Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–3.
- Trivedi S, Miao C, Al-Abdallat MM, Haddadin A, Alqasrawi S, Iblan I, et al. Inclusion of MERS-spike protein ELISA in algorithm to determine serologic evidence of MERS-CoV infection. J Med Virol. 2018;90:367–71.
- Centers for Disease Control and Prevention. Update and interim guidance on outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China; 2020 Jan 17 [cited 2020 Apr 5]. https://emergency.cdc.gov/han/han00426.asp
- Kujawski SA, Wong KK, Collins JP, Epstein L, Killerby ME, Midgley CM, et al.; COVID-19 Investigation Team. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020.
- Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al.; Investigation Team. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill. 2020;25:
- Burke RM, Midgley CM, Dratch A, Fenstersheib M, Haupt T, Holshue M, et al. Active monitoring of persons exposed to patients with confirmed COVID-19—United States, January–February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:245–6.
- Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, et al.; Illinois COVID-19 Investigation Team. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020;395:1137–44.
- Scott SE, Zabel K, Collins J, Hobbs KC, Kretschmer MJ, Lach M, et al. First mildly ill, non-hospitalized case of coronavirus disease 2019 (COVID-19) without viral transmission in the United States—Maricopa County, Arizona, 2020. Clin Infect Dis. 2020 Apr 2 [Epub ahead of print].
- Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) cases in the U.S.; 2020 [cited 2020 Apr 20]. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
- Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177–9.
- Cheng VC, To KK, Tse H, Hung IF, Yuen KY. Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev. 2012;25:223–63.
- Ng K, Poon BH, Kiat Puar TH, Shan Quah JL, Loh WJ, Wong YJ, et al. COVID-19 and the risk to health care workers: a case report. [ Mar 16 ] [Epub ahead of print]. Ann Intern Med. 2020;
- Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;
- To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–74.
Suggested citation for this article: Chu VT, Freeman-Ponder B, Lindquist S, Spitters C, Kawakami V, Dyal JW, et al. Investigation and serologic follow-up of contacts of an early confirmed case-patient with COVID-19, Washington, United States. Emerg Infect Dis. 2020 Aug [date cited]. http://dx.doi.org/10.3201/eid2608.201423
Original Publication Date: May 29, 2020
1These authors contributed equally to this article.